EndoBarrier treatment for longstanding type 2 diabetes and obesity: A comparison of the outcomes with an implantation period of 9 months versus 12 months in 90 consecutive EndoBarrier treated patients RESULTS Table 1: 78/90 (87%) patients attended review at both 9-months and 12-months after EndoBarrier implantation. Baseline characteristics: .

Authors: REJ Ryder, M Yadagiri, W Burbridge, SP Irwin, T Bashir, MC Wyres, ML Cull, JP Bleasdale, RA Allden, EN Fogden, M Anderson and P Sen Gupta.

The Diabetes UK Professional Conference 2023 is taking place on the 26th to 28th April 2023 at the Exhibition Centre Liverpool.

ABCD are delighted to join Diabetes UK at their Professional Conference with a live session as part of their engaging two-day programme.

Hear from our committee members on Wednesday 26 April 2023, from 13.15 to 14.10.

Our session will be chaired by Dipesh Patel (London), ABCD Chair.

As healthcare professionals, we strive to provide the best possible care for people with type 1 diabetes. One of the most challenging aspects of managing this condition is achieving and maintaining blood glucose levels within a safe and healthy range. The development of hybrid closed-loop systems, which combine continuous glucose monitoring and insulin pump therapy with advanced algorithms to automate insulin delivery, represents a significant advance in diabetes care.

Data from the ABCD worldwide EndoBarrier registry published in the current issue of Diabetes Care

1022 patients, 34 centres, 10 countries, shows improvements in weight, glycaemic control and CVD risk factors. EndoBarrier is a potential future treatment option.

https://diabetesjournals.org/care/article-pdf/46/4/e89/700530/dc221952…

The Diabetes Technology Network UK (DTN-UK) are looking for three people with diabetes, who have personal experience of using wearable diabetes technologies (CGM/pump/closed-loop systems) to join the committee of DTN-UK, part of the Association of British Clinical Diabetologists (ABCD).

DTN-UK is an organisation which exists to support UK health care professionals involved in using technology designed to improve the lives of people living with diabetes.

Endoscopic proximal intestinal exclusion can improve non-alcoholic fatty liver disease (NAFLD) in patients with diabesity.

Presented by: B Hayee

Authors:

Hayee B, Sen Gupta P, Anderson M, Fogden E, Roy AA, Butler DB, Bajwa RS, Amiel SA, Ryder REJ.

Endoscopic proximal intestinal exclusion with Endobarrier bringing simultaneous benefit to both diabesity and obstructive sleep apnoea(OSA) requiring overnight continuous positive airway pressure ventilation(CPAP)- Case reports

Authors:

M Yadagiri, MH Lang, AAS Mohammed, N Nathani, AB Rajasekharan, JP Bleasdale, EN Fogden, MR Anderson, P Sen Gupta, REJ Ryder.

A reminder to ABCD members that voting closes soon (3 April, midday) for the Royal College of Physicians elected councillors.

Two diabetologists are standing for election: